✦ LIBER ✦

The development of a recombinant Babesia vaccine

✍ Scribed by I.G. Wright; R. Casu; M.A. Commins; B.P. Dalrymple; K.R. Gale; B.V. Goodger; P.W. Riddles; D.J. Waltisbuhl; I. Abetz; D.A. Berrie; Y. Bowles; C. Dimmock; T. Hayes; H. Kalnins; G. Leatch; R. McCrae; P.E. Montague; I.T. Nisbet; F. Parrodi; J.M. Peters; P.C. Scheiwe; W. Smith; K. Rode-Bramanis; M.A. White

Book ID: 107949371
Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 691 KB
Volume: 44
Category: Article
ISSN: 0304-4017
DOI: 10.1016/0304-4017(92)90138-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Application of exoantigens of Babesia an

Application of exoantigens of Babesia and Plasmodium in vaccine development

✍ M.A. James 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 709 KB

Vaccine development: Recombinant vaccini

Vaccine development: Recombinant vaccinia for prevention of hepatitis B

✍ Beale, John 📂 Article 📅 1984 🏛 Nature Publishing Group 🌐 English ⚖ 261 KB

Novel vaccination for control of the Bab

Novel vaccination for control of the Babesia vector, Boophilus microplus

✍ P. Willadsen; D.H. Kemp 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 124 KB

Strategies for the development of recomb

Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer

✍ Jeffrey Schlom; Judy Kantor; Scott Abrams; Kwong Y. Tsang; Dennis Panicali; J. M 📂 Article 📅 1996 🏛 Springer US 🌐 English ⚖ 999 KB

Progress in development and testing of n

Progress in development and testing of novel recombinant vaccine platforms for HIV

✍ Weiner, David B. 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 55 KB

Safety and immunogenicity of a recombina

Safety and immunogenicity of a recombinant hepatitis B vaccine

✍ E. Dandolos; A. Roumeliotou-Karayannis; S. C. Richardson; Prof. G. Papaevangelou 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB

A hepatitis B vaccine produced in yeast by recombinant DNA technology was evaluated using 5-micrograms and 10-micrograms doses in a randomized trial lasting 7 months in 110 male armed forces recruits aged 17-19 years. Results were compared to those of an identical trial of a plasma-derived vaccine.